Donepezil for the symptomatic treatment of patients with mild to moderate Alzheimer's disease: a meta‐analysis of individual patient data from randomised controlled trials

安慰剂 多奈哌齐 耐受性 医学 内科学 优势比 不利影响 阿尔茨海默病 置信区间 随机对照试验 痴呆 疾病 病理 替代医学
作者
Anne Whitehead,Carlos Perdomo,Raymond D. Pratt,Jacqueline Birks,Gordon Wilcock,John Grimley Evans
出处
期刊:International Journal of Geriatric Psychiatry [Wiley]
卷期号:19 (7): 624-633 被引量:154
标识
DOI:10.1002/gps.1133
摘要

Abstract Background The objective was to evaluate the efficacy and tolerability of donepezil (5 and 10 mg/day) compared with placebo in alleviating manifestations of mild to moderate Alzheimer's disease (AD). Method A systematic review of individual patient data from Phase II and III double‐blind, randomised, placebo‐controlled studies of up to 24 weeks and completed by 20 December 1999. The main outcome measures were the ADAS‐cog, the CIBIC‐plus, and reports of adverse events. Results A total of 2376 patients from ten trials were randomised to either donepezil 5 mg/day ( n = 821), 10 mg/day ( n = 662) or placebo ( n = 893). Cognitive performance was better in patients receiving donepezil than in patients receiving placebo. At 12 weeks the differences in ADAS‐cog scores were 5 mg/day–placebo: − 2.1 [95% confidence interval (CI), − 2.6 to − 1.6; p < 0.001], 10 mg/day–placebo: − 2.5 ( − 3.1 to − 2.0; p < 0.001). The corresponding results at 24 weeks were − 2.0 ( − 2.7 to − 1.3; p < 0.001) and − 3.1 ( − 3.9 to − 2.4; p < 0.001). The difference between the 5 and 10 mg/day doses was significant at 24 weeks ( p = 0.005). The odds ratios (OR) of improvement on the CIBIC‐plus at 12 weeks were: 5 mg/day–placebo 1.8 (1.5 to 2.1; p < 0.001), 10 mg/day–placebo 1.9 (1.5 to 2.4; p < 0.001). The corresponding values at 24 weeks were 1.9 (1.5 to 2.4; p = 0.001) and 2.1 (1.6 to 2.8; p < 0.001). Donepezil was well tolerated; adverse events were cholinergic in nature and generally of mild severity and brief in duration. Conclusion Donepezil (5 and 10 mg/day) provides meaningful benefits in alleviating deficits in cognitive and clinician‐rated global function in AD patients relative to placebo. Increased improvements in cognition were indicated for the higher dose. Copyright © 2004 John Wiley & Sons, Ltd.
最长约 10秒,即可获得该文献文件

科研通智能强力驱动
Strongly Powered by AbleSci AI
更新
大幅提高文件上传限制,最高150M (2024-4-1)

科研通是完全免费的文献互助平台,具备全网最快的应助速度,最高的求助完成率。 对每一个文献求助,科研通都将尽心尽力,给求助人一个满意的交代。
实时播报
1秒前
2秒前
坦率的薯片完成签到,获得积分20
2秒前
2秒前
一一应助小巧的诗双采纳,获得10
2秒前
小马甲应助虚心以蓝采纳,获得10
3秒前
4秒前
5秒前
5秒前
邮一颗树莓关注了科研通微信公众号
5秒前
思源应助karin1886采纳,获得30
5秒前
ml发布了新的文献求助10
5秒前
邓佳鑫Alan应助将将采纳,获得10
5秒前
852应助Sherling采纳,获得10
6秒前
6秒前
JamesPei应助launcherray采纳,获得30
6秒前
哒哒发布了新的文献求助10
8秒前
8秒前
清爽难胜完成签到,获得积分10
8秒前
sfdf发布了新的文献求助10
8秒前
restudy68发布了新的文献求助10
8秒前
10秒前
10秒前
会编程真是太好了完成签到 ,获得积分10
10秒前
上官若男应助木木木采纳,获得10
11秒前
Yang发布了新的文献求助10
11秒前
liqunfang完成签到,获得积分20
11秒前
12秒前
12秒前
HouMQ发布了新的文献求助10
12秒前
陈祥薇发布了新的文献求助10
12秒前
化学发布了新的文献求助10
13秒前
14秒前
rose发布了新的文献求助10
14秒前
司空若剑发布了新的文献求助10
14秒前
GRG完成签到 ,获得积分10
14秒前
帝国之花发布了新的文献求助30
14秒前
稳重的谷南完成签到,获得积分10
14秒前
汉堡包应助哒哒采纳,获得10
15秒前
orixero应助星星啊啊啊啊采纳,获得10
15秒前
高分求助中
The late Devonian Standard Conodont Zonation 2000
Nickel superalloy market size, share, growth, trends, and forecast 2023-2030 2000
The Lali Section: An Excellent Reference Section for Upper - Devonian in South China 1500
Smart but Scattered: The Revolutionary Executive Skills Approach to Helping Kids Reach Their Potential (第二版) 1000
Very-high-order BVD Schemes Using β-variable THINC Method 830
Mantiden: Faszinierende Lauerjäger Faszinierende Lauerjäger 800
PraxisRatgeber: Mantiden: Faszinierende Lauerjäger 800
热门求助领域 (近24小时)
化学 医学 生物 材料科学 工程类 有机化学 生物化学 物理 内科学 纳米技术 计算机科学 化学工程 复合材料 基因 遗传学 催化作用 物理化学 免疫学 量子力学 细胞生物学
热门帖子
关注 科研通微信公众号,转发送积分 3248312
求助须知:如何正确求助?哪些是违规求助? 2891711
关于积分的说明 8268289
捐赠科研通 2559658
什么是DOI,文献DOI怎么找? 1388504
科研通“疑难数据库(出版商)”最低求助积分说明 650772
邀请新用户注册赠送积分活动 627733